Somatonorm post-marketing surveillance study (UK and Ireland, 1986-1987): a preliminary report
| Autor: | Wild Rn |
|---|---|
| Rok vydání: | 1988 |
| Předmět: |
Adult
Male Pediatrics medicine.medical_specialty Adolescent Lipodystrophy Postmarketing surveillance Preliminary report medicine Humans Child Lipoatrophy Growth Disorders business.industry Somatrem Human Growth Hormone Incidence (epidemiology) Puberty Infant General Medicine medicine.disease Body Height Child Preschool Growth Hormone Pediatrics Perinatology and Child Health Female business GH Deficiency medicine.drug |
| Zdroj: | Acta paediatrica Scandinavica. Supplement. 343 |
| ISSN: | 0300-8843 |
| Popis: | A PMS study in the UK and Ireland recruited 581 children, mainly with GH deficiency, for treatment with Somatonorm and observation for 1 year; only 1 child proved totally non-evaluable. The mean dose prescribed was 0.41 IU/kg/week, with 56% of children receiving below the recommended dose. Underdosing was reflected particularly by the low growth rates of pubertal children. Somatonorm was safe, with a low incidence of reported events, of which lipoatrophy (in 6 cases) was the most common. Antibody assays were seldom requested and always negative. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|